A designed Tat immunogen generates enhanced anti-Tat C-terminal antibodies

Vaccine

Volumn 30, Issue 14, 2012, Pages 2453-2461

  Liao, Wenting ^a   Chen, Qiuli ^a   Cao, Jie ^a   Tan, Guangguo ^a   Zhu, Zhenyu ^a   Zhang, Huaqun ^a   Chai, Yifeng ^a   Pan, Wei ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

HIV 1 Tat; Tat(B41 100C); Tat(B41 100N); Vaccine

Indexed keywords

ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 TAT VACCINE; RECOMBINANT PROTEIN; RECOMBINANT TAT IMMUNOGEN; TAT C TERMINAL ANTIBODY; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; FEMALE; HIV ANTIBODIES; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDES; RABBITS; RECOMBINANT FUSION PROTEINS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84862830205     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.055     Document Type: Article

References (48)

1. Campbell G.R., Loret E.P. What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine?. Retrovirology 2009, 6:50.
2. Serriere J., Dugua J.M., Bossus M., Verrier B., Haser R., Gouet P., et al. Fab'-induced folding of antigenic N-terminal peptides from intrinsically disordered HIV-1 Tat revealed by X-ray crystallography. J Mol Biol 2010, 405(January (1)):33-42.
3. Lorey S., Stockel-Maschek A., Faust J., Brandt W., Stiebitz B., Gorrell M.D., et al. Different modes of dipeptidyl peptidase IV (CD26) inhibition by oligopeptides derived from the N-terminus of HIV-1 Tat indicate at least two inhibitor binding sites. Eur J Biochem 2003, 270(May (10)):2147-2156.
4. Gutheil W.G., Subramanyam M., Flentke G.R., Sanford D.G., Munoz E., Huber B.T., et al. Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): a possible mechanism for Tats immunosuppressive activity. Proc Natl Acad Sci U S A 1994, 91(July (14)):6594-6598.
5. Wrenger S., Faust J., Mrestani-Klaus C., Fengler A., Stockel-Maschek A., Lorey S., et al. Down-regulation of T cell activation following inhibition of dipeptidyl peptidase IV/CD26 by the N-terminal part of the thromboxane A2 receptor. J Biol Chem 2000, 275(July (29)):22180-22186.
6. Tahirov T.H., Babayeva N.D., Varzavand K., Cooper J.J., Sedore S.C., Price D.H. Crystal structure of HIV-1 Tat complexed with human P-TEFb. Nature 2009, 465(June (7299)):747-751.
7. Anand K., Schulte A., Vogel-Bachmayr K., Scheffzek K., Geyer M. Structural insights into the cyclin T1-Tat-TAR RNA transcription activation complex from EIAV. Nat Struct Mol Biol 2008, 15(December (12)):1287-1292.
8. Ruben S., Perkins A., Purcell R., Joung K., Sia R., Burghoff R., et al. Structural and functional characterization of human immunodeficiency virus tat protein. J Virol 1989, 63(January (1)):1-8.
9. Vives E., Brodin P., Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997, 272(June (25)):16010-16017.
10. Chang H.C., Samaniego F., Nair B.C., Buonaguro L., Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 1997, 11(October (12)):1421-1431.
11. Ensoli B., Buonaguro L., Barillari G., Fiorelli V., Gendelman R., Morgan R.A., et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993, 67(January (1)):277-287.
12. Demirhan I., Chandra A., Mueller F., Mueller H., Biberfeld P., Hasselmayer O., et al. Antibody spectrum against the viral transactivator protein in patients with human immunodeficiency virus type 1 infection and Kaposi's sarcoma. J Hum Virol 2000, 3(May-June (3)):137-143.
13. Krone W.J.A., Debouck C., Epstein L.G., Heutink P., Meloen R., Goudsmit J. Natural antibodies to HIV-Tat epitopes and expression of HIV-1 genes invivo. J Med Virol 1988, 26(November (3)):261-270.
14. Rezza G., Fiorelli V., Dorrucci M., Ciccozzi M., Tripiciano A., Scoglio A., et al. The presence of anti-Tat antibodies is predictive of long-term nonprogression to aids or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J Infect Dis 2005 Apr, 191(8):1321-1324.
15. Bellino S., Francavilla V., Longo O., Tripiciano A., Paniccia G., Arancio A., et al. Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate. Rev Recent Clin Trials 2009, 4(September (3)):195-204.
16. Ensoli B., Bellino S., Tripiciano A., Longo O., Francavilla V., Marcotullio S., et al. Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One 2010, 5(11):e13540.
17. Cafaro A., Caputo A., Fracasso C., Maggiorella M.T., Goletti D., Baroncelli S., et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med 1999, 5(June (6)):643-650.
18. Stittelaar K.J., Gruters R.A., Schutten M., van Baalen C.A., van Amerongen G., Cranage M., et al. Comparison of the efficacy of early versus late viral proteins in vaccination against SIV. Vaccine 2002, 20(July (23-24)):2921-2927.
19. Liang X., Casimiro D.R., Schleif W.A., Wang F., Davies M.E., Zhang Z.Q., et al. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys. J Virol 2005, 79(October (19)):12321-12331.
20. Gregoire C.J., Loret E.P. Conformational heterogeneity in two regions of TAT results in structural variations of this protein as a function of HIV-1 isolates. J Biol Chem 1996, 271(September (37)):22641-22646.
21. Foucault M., Mayol K., Receveur-Brechot V., Bussat M.C., Klinguer-Hamour C., Verrier B., et al. UV and X-ray structural studies of a 101-residue long Tat protein from a HIV-1 primary isolate and of its mutated, detoxified, vaccine candidate. Proteins 2010, 78(May (6)):1441-1456.
22. Ma M., Nath A. Molecular determinants for cellular uptake of Tat protein of human immunodeficiency virus type 1 in brain cells. J Virol 1997, 71(March (3)):2495-2499.
23. Opi S., Peloponese J.M., Esquieu D., Watkins J., Campbell G., De Mareuil J., et al. Full-length HIV-1 Tat protein necessary for a vaccine. Vaccine 2004, 22(August (23-24)):3105-3111.
24. Moreau E., Belliard G., Partidos C.D., Pradezinsky F., Le Buanec H., Muller S., et al. Important B-cell epitopes for neutralization of human immunodeficiency virus type 1 Tat in serum samples of humans and different animal species immunized with Tat protein or peptides. J Gen Virol 2004, 85(October (Pt 10)):2893-2901.
25. Noonan D.M., Gringeri A., Meazza R., Rosso O., Mazza S., Muca-Perja M., et al. Identification of immunodominant epitopes in inactivated Tat-vaccinated healthy and HIV-1-infected volunteers. J Acquir Immune Defic Syndr 2003, 33(May (1)):47-55.
26. Opi S., Peloponese J.M., Esquieu D., Campbell G., de Mareuil J., Walburger A., et al. Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants. J Biol Chem 2002, 277(September (39)):35915-35919.
27. Chen L., Deng S., Cao J., He J., Chen Q., Jiang S., et al. Effective expression and immunogenicity analysis of HXB2 subtype Tat protein deleted the cysteine-rich region in E. coli. Chin J Microbiol Immunol 2008, 28(5):404-410.
28. Siddappa N.B., Venkatramanan M., Venkatesh P., Janki M.V., Jayasuryan N., Desai A., et al. Transactivation and signaling functions of Tat are not correlated: biological and immunological characterization of HIV-1 subtype-C Tat protein. Retrovirology 2006, 3.
29. Liao W., Tan G., Zhu Z., Chen Q., Lou Z., Dong X., et al. HIV-1 Tat induces biochemical changes in the serum of mice. Virology 2012, 422(2):288-296.
30. Gavioli R., Cellini S., Castaldello A., Voltan R., Gallerani E., Gagliardoni F., et al. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS. Vaccine 2008, 26(January (5)):727-737.
31. Ensoli B., Fiorelli V., Ensoli F., Lazzarin A., Visintini R., Narciso P., et al. The therapeutic phase I trial of the recombinant native HIV-1 Tat protein. AIDS 2008, 22(October (16)):2207-2209.
32. Longo O., Tripiciano A., Fiorelli V., Bellino S., Scoglio A., Collacchi B., et al. Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. Vaccine 2009, 27(May (25-26)):3306-3312.
33. Ensoli B., Fiorelli V., Ensoli F., Lazzarin A., Visintini R., Narciso P., et al. The preventive phase I trial with the HIV-1 Tat-based vaccine. Vaccine 2009, 28(2):371-378.
34. Verrier B., Le Grand R., Ataman-Onal Y., Terrat C., Guillon C., Durand P.Y., et al. Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08. DNA Cell Biol 2002, 21(September (9)):653-658.
35. Allen T.M., Mortara L., Mothe B.R., Liebl M., Jing P., Calore B., et al. Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol 2002, 76(April (8)):4108-4112.
36. Caselli E., Betti M., Grossi M.P., Balboni P.G., Rossi C., Boarini C., et al. DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat. J Immunol 1999, 162(May (9)):5631-5638.
37. Mayol K., Munier S., Beck A., Verrier B., Guillon C. Design and characterization of an HIV-1 Tat mutant: inactivation of viral and cellular functions but not antigenicity. Vaccine 2007, 25(August (32)):6047-6060.
38. Guillon C., Mayol K., Terrat C., Compagnon C., Primard C., Charles M.H., et al. Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits. Vaccine 2007, 25(October (43)):7491-7501.
39. Lecoq A., Moine G., Bellanger L., Drevet P., Thai R., Lajeunesse E., et al. Increasing the humoral immunogenic properties of the HIV-1 Tat protein using a ligand-stabilizing strategy. Vaccine 2008, 26(May (21)):2615-2626.
40. Shojania S., O'Neil J.D. HIV-1 Tat is a natively unfolded protein: the solution conformation and dynamics of reduced HIV-1 Tat-(1-72) by NMR spectroscopy. J Biol Chem 2006, 281(March (13)):8347-8356.
41. Viscidi R.P., Mayur K., Lederman H.M., Frankel A.D. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. Science 1989, 246(December (4937)):1606-1608.
42. Subramanyam M., Gutheil W.G., Bachovchin W.W., Huber B.T. Mechanism of HIV-1 Tat induced inhibition of antigen-specific T cell responsiveness. J Immunol 1993, 150(March (6)):2544-2553.
43. Bennasser Y., Contreras X., Moreau M., Le Clerc C., Badou A., Bahraoui E. HIV-1 Tat protein induces IL-10 production by human monocytes: implications of the PKC and calcium pathway. J Soc Biol 2001, 195(3):319-326.
44. Leghmari K., Bennasser Y., Bahraoui E. HIV-1 Tat protein induces IL-10 production in monocytes by classical and alternative NF-kappaB pathways. Eur J Cell Biol 2008, 87(December (12)):947-962.
45. Gupta S., Boppana R., Mishra G.C., Saha B., Mitra D. HIV-1 Tat suppresses gp120-specific T cell response in IL-10-dependent manner. J Immunol 2008, 180(January (1)):79-88.
46. Marinaro M., Riccomi A., Rappuoli R., Pizza M., Fiorelli V., Tripiciano A., et al. Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA. Vaccine 2003, 21(September (25-26)):3972-3981.
47. Kashi V.P., Jacob R.A., Paul S., Nayak K., Satish B., Swaminathan S., et al. HIV-1 Tat-specific IgG antibodies in high-responders target a B-cell epitope in the cysteine-rich domain and block extracellular Tat efficiently. Vaccine 2009, 27(November (48)):6739-6747.
48. Florese R.H., Demberg T., Xiao P., Kuller L., Larsen K., Summers L.E., et al. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol 2009, 182(March (6)):3718-3727.